This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access Genotropin® (somatropin, rbe) prescribing information and adverse event reporting can be found at the bottom of the page.

Genotropin has proven efficacy in paediatric growth hormone deficiency (pGHD)1 with achievement of genetic height potential2

Genotropin is indicated for the treatment of growth disturbance in children due to insufficient secretion of growth hormone (growth hormone deficiency, GHD). 

Prevalence of Paediatric GHD (pGHD)

The prevalence of paediatric growth hormone deficiency is estimated to be between 1 in 3500 and 1 in 4000 children. However, in about 50% of children the cause of growth hormone deficiency is unknown (idiopathic growth hormone deficiency).​​​​​​​7

Genotropin is effective in treating idiopathic pGHD​​​​​​​2

Achievement of genetic height potential2

Genetic height potential normalised by growth hormone (GH) treatment (0.65 IU/kg body weight/week)2

Genotropin is effective in treating idiopathic pGHD2​​​​​​​

Patients achieved their genetic height potential following treatment with growth hormone (0.65 IU/kg body weight/week for a median duration of 9.4 years)2 

Adapted from Cutfield et al, 1999 2

Study methods

Analysis of final height in idiopathic GHD patients enrolled in KIGS database. Of 10,657 idiopathic GHD patients enrolled from 43 participating countries, 369 fulfilled the necessary final height criteria for inclusion in the analysis and were treated on an average dose of 0.49 IU/kg body weight/week (0.16 mg/kg body weight/week) growth hormone (GH) for a median of 8.1 years. A Swedish subgroup of patients (n=69) received conventional therapy (0.65 IU/kg body weight/week) for a mean of 9.4 years. The criteria used to define final height were height velocity less than 2 cm/year, calculated over a minimum of 9 months; chronological age more 17 years or bone age of more than 16 years in boys; chronological age more than 15 years or bone age more than 14 years in girls. To be included in the analysis the children had to have more than 2 years of GH treatment prior to puberty, and more than 5 years of GH treatment in total.

Dosing​​​​​​​1

Dosage recommendations in Paediatric Patients

Indication

mg/kg body weight dose per day

mg/m2 body surface area dose per day

Growth hormone deficiency in children

0.025 - 0.035

0.7 - 1.0

Please refer to the Summary of Product Characteristics for full information before prescribing Genotropin

Safety​​​​​​​1

Adverse Events in the long-term treatment of Children with Growth Hormone Deficiency


Long-term Treatment of Children with Growth Disturbance due to insufficient secretion of growth hormone

System Organ Class

Very Common ≥ 1/10

Common ≥ 1/100 to <1/10

Uncommon ≥ 1/1,000 to <1/100

Rare ≥ 1/10,000 to <1/1,000

Very Rare <1/10,000


Not Known (cannot be estimated from available data)

Neoplasms Benign, Malignant and Unspecified (including cysts and polyps)

Leukaemia

Metabolism and Nutrition Disorders

Type 2 diabetes mellitus

Nervous System Disorders

Paraesthesia*
Benign intracranial hypertension

Skin and Subcutaneous Tissue Disorders

Rash**,
Pruritus**,
Urticaria*

Musculoskeletal, Connective Tissue and Bone Disorders

Arthralgia*

Myalgia*
Musculoskeletal stiffness*

General Disorders and Administration Site Conditions

Injection site reaction$

Oedema peripheral*
Face oedema*

Investigations

Blood cortisol decreased

*In general, these adverse effects are mild to moderate, arise within the first months of treatment, and subside spontaneously or with dose-reduction. The incidence of these adverse effects is related to the administered dose, the age of the patients, and possibly inversely related to the age of the patients at the onset of growth hormone deficiency.
** Adverse Drug Reactions (ADR) identified post-marketing
$ Transient injection site reactions in children have been reported.
‡ Clinical significance is unknown
† Reported in growth hormone deficient children treated with somatropin, but the incidence appears to be similar to that in children without growth hormone deficiency.

Explore more

NICE technology appraisal guidance

Find out more about NICE’s technology appraisals on the use of Genotropin for Adult Growth Hormone Deficiency

Find out more

Patient Transition

Learn more about how you can transition your patients from paediatric to adult care

Learn more

Abbreviations: GHD, growth hormone deficiency; GH, growth hormone.
References
  1. Genotropin Summary of Product Characteristics. Accessed here.
  2. Cutfield W, et al, 1999. Acta Paediatr; 428(Suppl): 72–75.
  3. De Zegher F, et al. J Clin Endocrinol Metab 2000; 85(8): 2816–2821.
  4. Ranke MB, Price DA, Reiter, 2007. Basel, Karger, pp 332–339.
  5. Ranke MB, Price DA, Reiter EO, 2007. Basel, Karger, pp 326–331.
  6. Lindgren AC, Ritzén EM, 1999. Acta Paediatr; 433(Suppl): 109–111.
  7. NICE Guideline [TA188]. Human growth hormone (somatropin) for the treatment of growth failure in children. Available here.
PP-GEN-GBR-1070. April 2021

Groassist

The Groassist app supports paediatric patients through their journey with growth hormone

Learn more

Starter kits

A choice of personalised starter kits is available to child and adult Genotropin patients to make sure they get off to a good start with their treatment

Find out more

The Genotropin Delivery portfolio

Learn more about the 3 devices available for Genotropin patients

Learn more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No